FDA OKs early-stage study of Inovio's Zika vaccine candidate; shares up 5% premarket

• Inovio Pharmaceuticals (NASDAQ:INO) is up 5% premarket on increased volume in response to its announcement that the FDA has approved the start of a Phase 1 clinical trial to evaluate its Zika DNA vaccine (GLS-5700) candidate in 40 healthy volunteers. The study will assess the safety, tolerability and immunogenicity of GLS-5700 administered via intradermal injection with CELLECTRA, the company's proprietary DNA delivery device.
• The company is developing GLS-5700 with Seoul, South Korea-based GeneOne Life Science.
• Previously: Inovio's Zika vaccine candidate shows robust immune response in preclinical testing; shares up 4% (Feb. 17)